Amid Amgen's similar struggles, AstraZeneca slams the brakes on MCL-1 blood cancer drug

AstraZeneca has paused an active phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing the need to suss out a potential safety issue.The trial suspension, noted only through ClinicalTrials.gov, came Oct. 19: “The study has been put on hold to allow further evaluation of safety related information,” the brief update said. AstraZeneca did not immediately respond to a request for comment on the trial’s suspension.